By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Tethys Bioscience today said that it has raised $33 million in venture financing and a loan.

The Emeryville, Calif.-based firm, which is developing biomarker-based, disease-risk tests, has raised $23 million in venture financing through new investors, including Greenspring Associates and Paul Capital Investments, and its current investors. The funds are part of Tethys' Series D round, bringing the total funding in that round to $48 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.